A randomized, double-blind, parallel-group clinical study found that treatment with RO5459072 slightly reduced B and CD8+T cells in SS patients, yet there was no significant improvement in disease activity and symptoms (144). The gene discussed is CD8A; the disease is synovial sarcoma.